Getting Type 2 Diabetes Mellitus Patients to Goal: The Role of New and Emerging Injectable Therapies
Activity Release Date: August 22, 2016
Expiration Date: August 31, 2018 (subject to change)
- NO CE Credit will be available after this date.
A post impact survey invitation will be sent to all learners who complete this activity (see below). Participation is completely optional.
The management of type 2 diabetes mellitus (T2DM) remains a major clinical challenge as many patients continue to struggle with achieving therapeutic targets. Despite recent advances in T2DM therapies, optimal glycemic control is often not achieved. The goal of this activity is to review the newest injectable therapies including basal analogs and GLP1s used in the treatment of T2DM.management.
Upon completion of this educational activity, the participant should be able to:
1) Describe the natural progression and pathogenesis of T2DM in relationship to personalized therapeutic options and treatment goals.
2) Review the newest injectable therapies including basal analogs and GLP1s used in the treatment of T2DM.
3) Identify best practices for selecting, initiating, and advancing appropriate injectable therapies to manage hyperglycemia and avoid hypoglycemia.
Dixie Harms, DNP, ARNP, FNP-C, BC-ADM, FAANP
Angela Thompson FNP-C, BC-ADM, CDE
This CE activity is planned in accordance with AANP Accreditation Policies and Standards. It is supported by an educational grant from Novo Nordisk Inc. The speakers disclose the following relevant affiliations: Dixie Harms: Novo Nordisk, Inc. and Angela Thompson, Medtronic, Inc.
This educational activity may contain opinions of the speaker from their personal experience. The activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.
Post Impact Survey:
Between 30 to 90 days after this activity is completed, AANP will send out an invitation to participate in a Post Impact Outcomes Survey (PI Survey) . Participation in the survey is optional and does not affect the credit earned. The PI surveys help measure the overall impact of the education content, see how the material impacts practice behaviors and what changes are being made. This anonymous information is crucial in helping the Education department improve current activities as well as guiding AANP in planning future CE activities.
To complete the CE for this activity review all the content, successfully complete the online post-test and online program evaluation.
For questions or more information concerning this online CE opportunity please contact the AANP CE Center Manager at CECenter@aanp.org.